Singapore is bustling with significant pharmaceutical advancements, with various key players making notable strides in the industry. The recent pharma news encompasses several groundbreaking initiatives shaping the region’s medical landscape.
Johnson & Johnson Innovation recently unveiled the Singapore QuickFire Challenge during the Singapore Week of Innovation and Technology (SWITCH). This challenge seeks to award innovators with a promising solution in life sciences, providing a grant pool of USD 100,000 for further development.
Evotec’s launch of 65LAB in partnership with global investors aims to advance drug discovery in Singapore. Collaborating with prominent entities, including A*STAR, NUS, and Duke-NUS Medical School, the venture aims to leverage the country’s academic and research excellence.
HealthTech Advancements and Pharmaceutical Milestones
MiyaHealth, a SaaS HealthTech company, secured ISO certification and a CE Mark for its Chronic Disease Management Platform, GensuApp. This platform, focusing on diabetes management, received recognition as a Class 1 medical device and is set to be introduced in Europe.
BeiGene’s cancer drug, zanubrutinib, has been added to Singapore’s Ministry of Health Cancer Drug List for multiple indications. This inclusion allows its reimbursement under healthcare schemes, benefiting Singaporean citizens and Permanent Residents.
Furthermore, Novo Nordisk acquired the late-stage investigational hypertension drug, ocedurenone, from Singapore-based KBP Biosciences in a significant deal worth up to $1.3 billion. This acquisition underlines Novo Nordisk’s commitment to advancing treatments for chronic kidney disease and uncontrolled hypertension.
Flagship Pioneering Expands to Singapore, Fueling Asia-Pacific Healthcare Collaborations
Another significant development involves the expansion of Flagship Pioneering, a US-based life sciences venture firm, which opened an office in Singapore. This expansion aims to foster collaborations within the Asia-Pacific healthcare and life sciences industry.
Crown Bioscience and JSR Life Sciences’ collaboration marked the opening of a new laboratory in Singapore. This facility will cater to preclinical and translational oncology drug discovery and development, offering a wide range of models and analytical biomarker capabilities.
These significant advancements underscore Singapore’s burgeoning role in pharmaceutical innovation and its commitment to addressing healthcare challenges through groundbreaking solutions and strategic collaborations.
Resource: Pharma Boardroom, November 29, 2023
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
